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ABSTRACT 
 
Complex Regional Pain Syndrome (CRSP) is a neuropathic disorder that 
has proven to be particularly difficult to treat based on the wide array of 
symptoms experienced by patients and the ambiguity surrounding their origin.  
The vast majority of treatment options today deal with the management of pain 
symptoms experienced by patients as a result of neuroinflammation.  Physical 
therapy is an instrumental aspect of the treatment plan; however the need for 
more effective pharmacological interventions is paramount.  
This study reviews a large volume of current and fundamental literature 
covering the plethora of treatment options currently used for CRPS.  Data from 
double blind clinical trials as well as observational clinical results were gathered 
in hopes of illuminating the efficacy of each treatment.  The goal was to assess 
current and future treatment options and determine what interventions are 
optimal for the management of CRPS. 
Furthermore, this review highlights some of the limitations of the current 
treatment options, in addition to providing a synopsis of CRPS as it is understood 
today.  This paper paints a picture of where we have been in the treatment of 
CRPS, what is working, what is not working, and where we might go in the future.   
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 1 
INTRODUCTION  
 
 CRPS is a relatively new distinction that is used to describe a range of 
symptoms that are associated with neuropathic pain arising after trauma. CRPS 
is usually the result of a localized injury to an extremity with typical spreading and 
worsening of symptoms in the afflicted region (Birklein, 2005). The injury can and 
usually is minor in nature, often coming in the form of a trivial sprain or bone 
fracture. More severe injuries have been known to be associated with CRPS, 
such as peripheral nerve damage. A further classification of CRPS has been 
established to account for cases in which nerve damage is present. CRPS type 1 
usually manifests after a trivial injury as mentioned above and does not include 
any nerve damage. CRPS type 2 results after direct peripheral nerve damage 
and is typically more severe than type 1. 
 CRPS has been known by many other names such as Reflex Sympathetic 
Dystrophy (RSD), Causalgia, and Sudek Atrophy. The origin and diagnostic 
criteria of the disorder have proven elusive to physicians. Under the RSD 
terminology, the pain associated with CRPS was believed to be associated with a 
reflex arc and thus a direct result of nerve damage (Rho et al., 2002).  Recently 
however, this notion has lost favor as there are cases of CRPS that do not 
present with any nerve damage whatsoever. The confusion surrounding the 
syndrome was addressed by Dr. Norman Harden who proposed a set of criteria 
that is used to clinically diagnose CRPS (Harden, 2007).  His consensus 
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determined that an irritating or noxious event triggers CRPS or results in a 
prolonged period of immobilization, which then leads to CRPS.  Additionally, 
CRPS presents with continuing pain or hyperalgesia, which is an increased 
sensitivity to pain, disproportionately to the stimulus of said pain.   The 
International Association for the Study of Pain finally established a diagnostic set 
of symptoms some or all of which may be present in patients suffering from 
CRPS (Table 1).  
 
 
Table 1: Criteria for the Clinical Diagnosis of CRPS.  The complexity of the 
syndrome and the diverse symptoms has created a degree of ambiguity for 
clinical diagnosis (Rho et al, 2002). 
 
The pain associated with CRPS is due to neuroinflammation with 
subsequent edema and hyperalgesia. CRPS typically has several symptoms and 
physical manifestations of neuroinflammation.  Most often CRPS manifests 
following trauma to one of the limbs. Following the trauma, primary afferent 
neurons are activated by locally released cytokines, which results in further 
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release of neuropeptides both locally and in the Central Nervous System (CNS) 
(Birklein, 2005).  The belief now is that it is the release of these neuropeptides 
that causes most of the symptoms of CRPS including the two most significant: 
pain and hyperalgesia (Birklein, 2005).  Most often the limb is characterized by 
erythema, hyperalgesia, allodynia, decreased motor function, and edema.  
Patients have a difficult time performing simple daily tasks with the affected limb. 
CRPS is often accompanied by several psychological and psychosocial 
conditions including depression, anxiety, and reduced quality of life (Lohnberg 
and Altmaier, 2012).  
 Several non-surgical treatment options exist for CRPS including physical 
therapy, drug intervention, and sympathetic block (Rho et al., 2002). Physical 
therapy can be effective in restoring motor function; however the severe pain 
associated with movement makes physical therapy extremely difficult and taxing 
on the patient.  As a result of the grueling physical therapy and prolonged period 
of pain, antidepressants are commonly administered to patients afflicted with 
CRPS.  Pharmacological interventions such as gabapentin, antidepressants, and 
opioids together have been shown to manage pain in patients (Figure 1). 
Recently Forouzanfar et al. concluded that the use of sympathetic block is largely 
ineffective in reducing pain symptoms in patients with CRPS, but remains a 
viable treatment option for some patients (Forouzanfar, 2002).   Additionally, new 
studies utilizing ketamine, naltrexone, and thalidomide have shown promise in 
curtailing the pain associated with CRPS. 
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Figure 1- Drug Therapy for CRPS. Some of the dosages and drugs currently 
utilized for treatment of CRPS. Patients are subject to a plethora of treatments, 
each of which varies based on individual patients (Rho et al., 2002). 
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TRADITIONAL TREATMENTS  
 
Gabapentin 
 
 One of the most commonly prescribed and effective drug treatments for 
CRPS is the anti-epileptic drug, Gabapentin, which has traditionally been used 
for its role as an anti-conversant (Chadwick, 1992).  Although initially only used 
to quell epileptic seizures, patients taking Gabapentin started noticing its 
potential use against neuropathic pain and hyperalgesia.  Initially the mechanism 
of action and scope of potential uses of gabapentin remained a mystery, which 
fueled several studies into the drug’s use in CRPS. In 1999, a study by Dr. Anton 
van de Vusse investigated 58 adults diagnosed with CRPS type 1 all 
experiencing a pain score greater than 3 out of 10 (Vusse, 2004).  All of the 
patients had previously been unsuccessfully treated with opioids, non-steroidal 
anti-inflammatory drugs, or sympathetic block.   
 The double blind treatment consisted of a 3 phase trial in which group A 
received gabapentin followed by a washout period, followed by a placebo.  Group 
B’s treatment was the opposite starting with the placebo and concluding with 
Gabapentin.  The “medication” period, which was either the placebo or 
Gabapentin, lasted 3 weeks followed by a 2 week washout period sufficient 
enough to expel any of the drug from the system.  Patients were evaluated at 
three, five, and eight weeks after the onset of treatment for various pain criteria.  
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Patients were asked to present a global perceived effect, essentially recording 
how they felt overall, as well as a 1-10 neuropathic pain score.  The affected 
limbs were also tested for nerve sensibility and allodynia through administration 
of pressure to the affected area.   
 The results showed a significant reduction in global perceived pain relief 
during the Gabapentin treatment.  47% of the patients on the gabapentin 
treatment reported that they experienced a reduction in pain, while only 17% of 
the patients taking the placebo experienced a reduction in pain (Figure 2).  
However the reduction in perceived pain was only seen in the group that took 
Gabapentin first, followed by the placebo.  Group B, those that took the placebo 
first, did not experience as significant reduction in pain. 
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a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
Figure 2-The Effect of Gabapentin on Global Perceived Pain- a) A 
comparison of reported pain relief between gabapentin and the placebo.  B) A 
statistically significant percentage of patients experienced a reduction in 
perceived pain on Gabapentin (Vusse et al., 2004) 
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Additionally the results showed a significant reduction in the sensory 
overstimulation in the Gabapentin users.  CRPS patients are often afflicted with 
hypersthesia, an increased sensation to the skin, which was shown to be 
dramatically reduced in the Gabapentin users.  The results suggested that 
Gabapentin has a mild effect on pain but an even greater effect on the 
hypersthesia associated with neuropathic pain (Vusse, 2004). 
 The study above suggests Gabapentin as a treatment option for CRPS; 
however it falls short of providing a standalone effective drug therapy.  In 2005, 
Dr. Gilron et al., investigated a joint therapy option using morphine in conjunction 
with gabapentin in an effort to illuminate some of gabapentin’s analgesic 
properties (Gilron, 2005).  The experiment used 4 research groups, each of 
which received daily doses of either placebo, morphine, gabapentin, or both 
gabapentin and morphine.  The study looked solely at pain using the traditional 
1-10 pain score as the quantifiable data and had a sample size of 41 patients, all 
suffering from neuropathic pain. The results showed an incremental decrease in 
pain from baseline to placebo, gabapentin, morphine, and finally gabapentin and 
morphine (Figure 3). 
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Figure 3: Gabapentin and Opioid use on Pain- A dramatic decrease in pain 
score from 5.72 to 3.06 when comparing baseline and a combination of 
gabapentin and morphine (Gilron, 2005). 
 
Furthermore, the combination of the two drugs produced a lower pain 
score on Short-Form McGill Pain Questionnaire than either drug on its own.  As a 
result of taking less of each of the two drugs on their own, when morphine and 
gabapentin are used in combination the side effects of each drug are 
dramatically reduced.  This is reflected in the Short-Form McGill Pain 
Questionnaire, which takes into account pain felt during everyday activities and 
adverse side-effects (Gilron, 2005).   
At this point, gabapentin has been established as a drug of choice in 
CRPS treatment.  The side effects associated with the drug are minimal, 
especially when compared to those of some of the other drugs used to combat 
CRPS.  Furthermore, the drug has been shown to alleviate pain on its own, but 
has also been shown to be especially effective when used in conjunction with 
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other interventions, most notably opioids.  While not a cure, gabapentin should 
be one of the first tools physicians use to manage CRPS, especially if opiates are 
included in the treatment plan. 
 
Antidepressants 
 
Chronic pain conditions and the discomfort associated with them has a 
link to major depression.  The link between depression and pain has been well 
established, and the use of selective serotonin reuptake inhibitors (SSRI) 
remains the gold standard treatment option (Blair, 2005). However, the use of 
tricyclic antidepressants (TCA) and serotonin and norepinephrine reuptake 
inhibitors (SNRI) provide other pharmacological options in the intervention of 
neuropathic pain.   
A literature review conducted by Dr. Matthew Blair summarizes the 
connection between major depression and pain (Blair, 2003).  The study 
examines a wide range of research studies from 1966 until 2002 that included 
both depression and pain as quantifiable data in a clinical trial.  Half of the data 
was categorized by subjects presenting with depression and then subsequently 
assessed for pain, and the other half as subjects presenting with pain and then 
assessed for depression. The results showed that 52% of patients presenting to 
pain clinics, were determined to have major depression (Blair, 2003).  
Furthermore, 27% of patients presenting with pain were determined to also show 
 11 
symptoms of depression, when treatment took place at a primary care facility.  
The strong difference between patients receiving a depression diagnosis after 
treatment at a pain clinic versus a primary care facility demonstrates the 
significant psychological effect of chronic pain.  Typically patients who are 
receiving treatment in a pain clinic have dealt with their pain for some time and 
have exhausted traditional treatment outlets such as urgent care facilities, 
hospitals, and primary care.  By the time treatment has been handed over to a 
pain specialist, the patient is familiar with their pain and its effect on their life.   
 Dr. Blair’s review also looked at the connection between pain 
improvement and secondary improvement of depression, while receiving 
treatment for only pain (Blair, 2003).  Although the data is hindered by a small 
sample size and uncontrolled studies, the results clearly demonstrate that 
improvement in depression and pain during treatment correlate with one another.  
What is more interesting is that all but 4 of the studies investigated by Dr. Blair 
used TCA as the antidepressant of choice during treatment.   
 TCAs are a class of compounds known as tertiary amines that function in 
the synaptic cleft (Sindrup, 2005).  The main method of action by which these 
compounds treat neuropathic pain and CRPS is through their ability to inhibit the 
reuptake of serotonin and noradrenalin from the synapse, back into the pre and 
postsynaptic neuron (Sindrup, 2005).  There has been some small evidence that 
TCA’s also show some binding properties to opioid receptors, which would help 
to explain why pain patients experience relief under TCA treatment, however the 
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binding affinity is too low to be a realistic source of pain alleviation (Hall, 1981). 
The leading evidence as to how TCA’s function in neuropathic pain treatment is 
through reuptake inhibition as mentioned, and the inhibition of voltage gated 
sodium channels (Lavoie, 1990).   
 The efficacy of TCA treatment is a stark contrast to the results collected 
from the use of SSRI’s for neuropathic and chronic pain.  SSRI treatment has 
been shown to be unsuccessful for pain in 1992 by Dr. Max and colleagues when 
they compared the results of 3 different antidepressants for the treatment of 
neuropathic pain, specifically in patients suffering from diabetic neuropathy (Max, 
1992).  Two double blind crossover studies were conducted, one of which 
compared Amitriptyline, an antidepressant of the TCA class, with a 
norepinephrine reuptake inhibitor, Desipramine, which is also a TCA 
antidepressant.  The other group received the SSRI, Fluoxetine or a placebo.  
The patients who took either of the TCA class antidepressants experienced a 
pain relief at least 20% greater than the placebo group.  However, only 48% of 
the experimental group that received the SSRI reported mild pain relief which is 
not statistically significant from the 41% of the placebo group that reported mild 
pain relief.  This suggests any drug in the TCA class can be utilized as an 
effective treatment option for neuropathic pain; however the SSRI class of 
antidepressants does not exhibit the same properties (Max, 1992).  The efficacy 
of both TCAs and SNRIs in treating neuropathic pain opens the door to further 
investigation of norepinephrine’s specific mechanism in pain alleviation.   
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 The typical treatment course for a CRPS patient involves not only the use 
of antidepressants but opioids as well.  The severity of pain and hyperalgesia 
associated with CRPS makes the use of opioids a cornerstone in treatment.  Of 
interest is the interaction between opioids and antidepressants and how they 
function together when combating pain.  A comparative study between opioids 
and antidepressants for neuropathic pain yielded supporting results for opioid, 
antidepressant, and joint treatment.  The double blind study, conducted by Dr. 
Raja and associates, compared treatment between seventy-six patients affected 
with postherpetic neuralgia, which is a condition characterized by nerve pain 
following shingles, varicella zoster viral infection (Raja, 2002).  Each of the 
seventy-six patients in the study underwent an eight week treatment period with 
morphine, desiparamine, and placebo.  The traditional 0-10 pain scale was used 
as a quantitative measurement as well as a 0-100 percentile scale of overall pain 
relief.  Both the opioids and the TCA showed an effective reduction of pain (1.9 
and 1.4 respectively) over the placebo (0.2); however more interesting is that the 
opioids fell short of showing a statistically significant advantage in pain relief over 
the TCA.  Furthermore, when the opioid and antidepressant were used in 
conjunction, 38% of patients experienced pain relief versus the 11% in the 
placebo group (Raja, 2002).   
 The significance of these results once again shows that antidepressants, 
in particular TCAs, are an effective treatment option for CRPS and neuropathic 
pain.  It is interesting to note here that of the patients that completed the opioid, 
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antidepressant, and placebo treatments, 54% preferred the opioid and only 30% 
preferred the antidepressant treatment.  The preference for the opioid treatment 
could be explained by the euphoric side effects of opioids of which 
antidepressants do not exhibit.  The greater takeaway however is that opioids 
and antidepressants appear to act independently of each other and can be 
synergistic.  This would indicate that an effective course of treatment for CRPS 
would include both opioids and antidepressants.   
 
Sympathetic Block 
 
  In order to understand how a sympathetic block might alleviate the pain 
felt by peripheral nerve injury, it is necessary to understand how nerve injury 
causes pain to begin with.  Normally, pain is an evolutionary response to a 
stimulus that causes damage to the body.  Pain is protective in that it alerts the 
body that whatever action taken is detrimental and thus should be avoided.  
Additionally, pain caused by an inflamed or damaged area prevents further 
manipulation before the body has had a chance to heal.  Neuropathic pain 
however is the result of an injury to the peripheral nerve, dorsal root, or the 
central nervous system, which often times causes prolonged, chronic pain 
(Woolf, 1999).  Neuropathic pain offers no biological advantage and is simply a 
maladaptive response by the body to lesions in the peripheral or central nervous 
system (Dworkin, 2003). Sympathetic block has been investigated as a potential 
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treatment option for neuropathic pain since the First World War.  In the simplest 
form, sympathetic block is the administration of an anesthetic to block the 
sympathetic nerve supply (Loh and Nathan, 1978).   
 One of the major limiting factors in the analysis of sympathetic block and 
CRPS is the degree to which the treatment has been studied.  Very few credible, 
double blind studies have been conducted investigating the extent to which the 
treatment actually alleviates pain in patients with CRPS.  However in 1988, Dr. 
Price compared the use of lidocaine versus saline when blocking sympathetic 
ganglia (Price 1998).  Patients provided a pain score before and after blockage 
and kept a pain diary for a week after treatment.  Unfortunately there was no true 
control group as each patient received both the lidocaine and the saline block.  
Each patient recorded massive reduction in pain 30 minutes after treatment with 
both the saline (68.7% reduction) and lidocaine (74.4% reduction).  The results 
are not statistically significant for the lidocaine block, suggesting a strong placebo 
effect.  However, the study did produce some optimistic results in the duration of 
pain relief.  The diary data noted a significantly prolonged period of relief after the 
lidocaine versus the saline injection (3 days 18 hours versus 19.9 hours) (Price 
1998).  
 Although, the highly reported pain relief experienced by the saline placebo 
group questions the results of this study, the statistically significant duration of 
pain relief between the two groups is encouraging.  This would suggest that 
sympathetic block may not acutely alleviate pain, but may play a role in chronic 
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pain reduction.  It is important to note the limitations of this study however.  The 
fact that each patient received both treatments could generate a bias in the 
reporting of acute pain reduction.  If the patients experienced pain relief after the 
lidocaine treatment, they may have reporting bias after a subsequent saline 
treatment.  Furthermore, a sample size of 7 CRPS patients for the study doesn’t 
generate enough data for confident reporting.   
 Extremely few studies investigating sympathetic block and neuropathic 
pain have been conducted, and even fewer have been done looking specifically 
into CRPS.  This limitation, as well as the ambiguous clinical and research data, 
makes drawing any conclusions for sympathetic block difficult.   One of the most 
comprehensive studies on the efficacy of intravenous regional sympathetic block 
for RSD was conducted in 1995 by Dr. Alejandro Jadad.  The diagnostic criteria 
for the study were set to include only patients suffering from severe cases of 
RSD and included the symptoms: persistent pain, hyperesthesia, edema, 
hyperhidrosis, color changes, and a history of injury that typically causes RSD 
(Jadad, 1995).  Guanethidine, an antihypertensive drug that travels across the 
sympathetic nerve membrane, was used for blockage.  Three different study 
groups were utilized: a high does guanethidine group, low dose guanethidine 
group, and a saline placebo group.  Injections were administered once a week, 
unless pain relief did not occur, in which the next scheduled treatment was 
postponed until results were seen.  Patients were asked to rate their pain severity 
and pain relief after each injection.  Pain scores were ultimately converted into a 
 17 
percentage of pain relief that was used as the primary data point for analysis.   
 Ideally patients would be administered an initial sympathetic block and 
would experience total pain relief, at which point no further injections would be 
necessary.  Surprisingly this result did occur in one of the sixteen subjects; 
however that patient is an outlier.  Five of the sixteen patients had to withdraw 
from the study due to hypotension, dizziness, and bradycardia experienced 
immediately after the first block, and lasting up to 24 hours.  The prevalence and 
severity of side effects and other minor complications arrested the study early for 
eight of the sixteen patients, leaving only 50% of the original sample group to 
provide complete data.  However, even of the patients that went on to finish the 
double blind trial, none of them reported a pain relief percentage greater than 
30% of the maximum.  Even worse, the severity of the side effects leads one to 
question the use of sympathetic block for pain relief at all (Jadad, 1995).    
 Although a common practice today, the experimental data behind 
sympathetic block as a possible treatment option for CRPS has shown confusing 
and conflicting results.  As mentioned above, studies have not shown a 
statistically significant advantage of sympathetic block over the placebo and have 
even been shown to cause detrimental effects.  Other studies have shown 
sympathetic block with the use of lidocaine to significantly decrease pain in 
CRPS patients (Wallace, 1964). Conflicting reports and the limitation caused by 
the lack of studies leaves sympathetic block more of a mystery than a potential 
treatment option, however its use continues today.  
 18 
Opioids 
 
Opioid treatment for acute pain is widespread and highly effective for both 
neuropathic and nociceptive pain.  With the hyperalgesia associated with CRPS, 
the use of opioids in the form of morphine, hydrocodone and oxycodone is 
unavoidable; however the chronic nature of CRPS suggests other treatment 
options as a more permanent solution to alleviate the symptoms of CRPS.  
Opioid tolerance and addiction are two issues that continue to plague CRPS 
treatment and the healthcare field as a whole.  The CDC reports that in 2012, 2 
million people used prescription opioids non-medically and in 2008 there were 
almost 15,000 deaths as a result of prescription pain abuse (CDC, 2008) (Figure 
4).  Although effective, the potential abuse and damage of opioids should 
eliminate their chronic use from the treatment plan for most cases of CRPS.  
Only the most severe cases and under strict observation should opioids be 
administered in a long-term treatment plan. 
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Figure 4: Prevalence of Opioid Abuse: The growing trend of non-
prescription opioid abuse is on the rise.  These numbers show the severity of the 
issue and the rationale as to why the chronic and even acute perscription of 
opioids should be heavily monitored (CDC, 2008). 
 
Tolerance is defined as a reduced sensitivity to a drugs effect, which can 
occur by several different pathways (Kieffer, 2002).  The leading theory as to how 
opioid tolerance develops hinges on the concept that opioid receptors become 
desensitized to the drug after prolonged exposure, thus diminishing binding of 
the ligand to the receptor.  On a molecular basis, the classic model for opioid 
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tolerance involves the phosphorylation of the opioid receptor and the binding of 
the compound, arrestin (Kieffer, 2002).  These two actions result in the 
uncoupling of the receptor to the intracellular G proteins.  Additionally, tolerance 
can result from a reduction in the amount of receptors present on the surface of 
the cell’s plasma membrane.  Receptors are internalized and broken down within 
the cell, resulting in fewer available surface receptors to bind opioids in the 
synapse (Figure 5).  The current theory is that tolerance results from a 
combination of these two events.  Furthermore, the initial response of the cell to 
opioid binding reduces cAMP levels, however after prolonged exposure opioid 
binding paradoxically results in increased cAMP within the cell (Kieffer, 2002).  
Although still unclear how this reversal might affect tolerance, the increase in 
cAMP has been shown to play a role in opioid withdrawal symptoms (Kieffer, 
2002).   
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Opioid Binding and Internalization: As opioid ligands continually bind to 
the receptor, uncoupling of the receptor to G proteins is triggered, resulting in 
decreased activity and receptor internalization (Kieffer, 2002).   
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The above theory provides a neat and simple conclusion to the question of 
how opioid tolerance arises, however recently a paradox involving morphine’s 
binding to opioid receptors has caused some to take another look at how 
tolerance develops.  The morphine paradox came to the forefront after prolonged 
morphine exposure showed that binding does not result in receptor 
internalization (Conner, 2004).  In actuality, some opioids do not result in 
receptor internalization, while others, like heroin, do.  Additionally, there may be 
several different forms of the opioid receptor in the brain, thus making specific 
interaction across all opioids more complex than originally suspected.   
 The question of how opioid tolerance arises is extremely complex and for 
now remains controversial.  The specific interactions of different opioids to 
different receptors in the brain still eludes our understanding today, and thus their 
use should be closely monitored when administering over a long period of time.  
There is no question that opiates are effective and should be used as an acute 
treatment option for CRPS; however tolerance and our ignorance to its 
manifestation argue against chronic opioid treatment. 
 One of the most troubling side effects of prolonged opioid exposure is the 
possible development of the exact symptom opioids are trying to combat: 
hyperalgesia.  Traditionally, the relationship between pain and opioid treatment 
has followed a linear trend: the more pain experienced, the more drug 
administered.  Patients suffering from chronic ailments such as cancer and 
CRPS may require large doses of opioids over a prolonged period of time, which 
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after an initially favorable response, may develop a paradoxical response such 
as hyperalgesia or allodynia (Mercadante, 2006).  The metabolic theory behind 
this phenomenon involves the activation of N-methyl-D-Aspartate (NMDA) 
receptors in the CNS.  NMDA activation leads to an increase in intracellular 
calcium, which then activates protein kinase C and increases the intracellular 
level of nitric oxide.  It has been shown that activation of protein kinase C and 
increased levels of nitric oxide can lead to hyperalgesia and pain states 
(Mercadante, 2006).  However, very little experimental data has been conclusive 
on what is occurring with opioid-induced hyperalgesia. This shortcoming again 
limits our understanding of prolonged opioid use.   
 
Ketamine 
 
 Ketamine infusion treatment targets the NMDA receptor.  NMDA receptor 
antagonists have been shown to inhibit the hyper excitability of nociceptive 
neurons in the spine, thus making NMDA receptors a primary target for pain 
suppression (Petrenko, 2003).  The investigation of NMDA receptors for pain has 
been relatively scarce until recently because of the complexity of pain in the 
human body versus animal models.  Historically, the application of successful 
pain treatments, such as NMDA blocks like dextromethorphan, has shown 
promise in animal studies, but has been complicated in human trials by the 
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complexity of pain and the more noticeable CNS effect that NMDA antagonists 
create.   
 Ketamine’s use in modern medicine is limited to anesthesia, where a high 
bolus dose produces a strong anesthetic effect.  However there is significant 
street value for the use of ketamine in smaller doses.  When snorted in small 
amounts, ketamine produces an effect similar to that of cocaine.  Users 
experience brief euphoria followed by a rush of energy.  However, when 
converted into a liquid form and injected directly into the blood stream, ketamine 
at higher doses produces powerful hallucination and psychotropic effects 
(Dotson, 1995).  Users experience what is known as a “K-hole” described as 
falling into a median between consciousness and the subconscious state which 
is typically produced by the higher anesthetic doses of ketamine (Dotson, 1995).  
The use of ketamine as a treatment for pain thus makes it dangerous at any 
dose, and especially dangerous for patients with bradycardia or hypotension as 
the drop in blood pressure and heart rate that results from ketamine’s anesthetic 
properties leaves patients vulnerable to fatal complications.  Additionally, 
ketamine has been shown to be highly addictive and is currently scheduled as a 
class 2 narcotic with the likes of marijuana and cocaine (Dotson, 1995).  The 
chronic abuse of ketamine has led to lower urinary tract complications, which are 
important to note before using the drug as a treatment option.  A review of 59 
ketamine abusers showed wide spread cystitis, hydronephrosis, and potentially 
irreversible renal damage (Chu et all, 2008).   
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 In spite of its potent neurotoxic side effects, ketamine has been shown to 
display promising pain alleviating properties, specifically in patients affected with 
CRPS.  In 2005, Dr. Correll conducted a retrospective study examining CRPS I 
and CRPS II patients receiving outpatient ketamine infusion treatments over a 7 
year period (Correll, 2005).  Ketamine infusions administered at a starting dose 
of 10mg/hr and were increased until the patients noted a feeling of inebriation.  A 
slow, incremental increase in ketamine is paramount in treatment as to avoid the 
side effects mentioned previously.  Additionally, each patient has a different 
optimal dosage before the onset of side effects, thus making ketamine treatment 
more of a continuum than a standard dose.  Patients provided a pain score and 
duration of pain relief, which was noted after each treatment for a maximum of 48 
hours.  Of the 33 patients included in the study, all of them experienced pain 
relief immediately after both the first and second treatment.  Additionally, 54% of 
patients experienced 3 months of pain relief after the first infusion, and 31% 
experienced pain relief after 6 months (Figure 6).   
 These results illuminate how powerful ketamine treatment can be for the 
relief of CRPS pain, however it is important to note the unintended effects each 
treatment had on the patients.  Side effects were experienced in all 33 patients.  
The most commonly experienced effects were inebriation, nausea, dizziness, 
and blurred vision.  As noted before, ketamine has extremely powerful CNS 
effects and although effective, treatment can be taxing on the patient.  
Furthermore 6 of the 33 patients experienced hallucinations and although none 
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of the patients in this study developed addictive behavior, widespread application 
of the treatment leaves room for addiction as an unwanted secondary 
development.  One troubling observation noted by researchers in the study 
shows that the onset of inebriation is essential in determining the optimal 
therapeutic dosage, which again leads back to the issue of exposing patients to a 
potentially addictive, powerful narcotic.   It should also be noted that four patients 
developed elevated liver enzymes after the first ketamine infusion, making 
careful monitoring of hepatic function essential for ketamine treatment.  The 
success of ketamine in alleviating pain in this study cannot be ignored, however 
the wide range of severe side effects hinder ketamine’s use to a tightly monitored 
in-patient treatment option. 
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Figure 6: Ketamine Infusion Pain Relief: a) patients experiencing pain relief 
after the first infusion started at 100% and maintained some pain relief for almost 
40 months. b) Duration of pain relief after a second ketamine infusion (Correll, 
2004) 
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Another study, conducted by Dr. Robert Schwartzman in 2009, achieved a 
more robust experimental set of criteria when examining ketamine’s use for 
CRPS (Schwartzman, 2009).  The study was engineered to only include severe 
cases of CRPS.  Patients had to have exhibited symptoms for a minimum of six 
months and had failed to respond to previous pharmacological interventions 
(opioids, NSAIDS, antidepressants, and muscle relaxants).  Before any treatment 
had started, every patient registered a baseline pain score through an extensive 
pain questionnaire including severity of pain, duration, location, degree, and 
effect on daily activity.  Dr. Schwartzman noted responses to different pain 
stimulants including: thermal, deep pressure and finger tap.  Both the ketamine 
and placebo group were administered treatment for a duration of 10 days, with 
data being collected after 5 initial days, 2 days off treatment, and then again after 
the final 5 days of treatment.   
 The overall scope of this experiment is extensive and provides the best 
data to available to date of ketamine’s treatment potential.  Data from the 26 
patients included in the study demonstrate a statistically significant reduction in 
pain across every variable investigated (Figure 7).  More interesting, is the lack of 
pain relief experienced by the placebo group.  Unlike sympathetic block with 
lidocaine, the control group here reported no change in pain score throughout the 
treatment, thus eliminating any potential bias (Schwartzman, 2009).   
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Figure 7: Pain Reduction in Ketamine over Placebo: A graphical 
representation of the statistically strong advantage ketamine has over the 
placebo in reducing pain experienced from CRPS (Schwartzman, 2009) 
 
 
Clearly from the data complied to date, the use of ketamine as a treatment 
option for CRPS is extremely promising.  Widespread application of ketamine is 
hindered by the strong side effects associated with the drug and by the lack of 
credible, double-blind studies conducted.  As of 2009 Dr. Schwartzman’s study of 
26 patients was the only study into ketamine’s use in CRPS that utilized a control 
group.  It is possible that physicians are hesitant to turn to ketamine because of 
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its dangerous side effects; however the nature of severe CRPS cases demands 
radical and progressive treatments.  
 
 
EXPERIMENTAL TREATMENTS  
 
Naltrexone  
 
 While only just recently investigated, low dose naltrexone has quickly 
emerged as a potential treatment option for CRPS (Chopra, 2013).  The theory 
behind the use of naltrexone centers on the neuroinflammatory characteristics of 
CRPS.  Once CRPS has progressed pass the use of traditional treatment 
options, suppression of the neuroinflammation causing hyperalgesia and CRPS 
symptoms becomes paramount.  The activation of inflammation is brought on by 
the upregulation of TLR4 (Toll-Like Receptor 4) in microglia (Chopra, 2013).  It 
has been shown that upregulation of TRL4 has directly resulted in neuropathic 
pain, thus making the downregulation of TRL4 a prime candidate for the relief of 
neuropathic pain and subsequently CRPS.  The upregulation of TRL4, through 
several molecular pathways, results in the release of cytokines, which cause 
pain.  Naltrexone is a TRL4 antagonist and serves as an option for the 
downregulation of TRL4.  
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 Traditionally, naltrexone has been used as an opiate antagonist.  Heroin 
abusers on the verge of overdose are administered naltrexone as a way to 
reverse the severe bradycardia and lethargy experienced.  Recently Dr. Chopara 
noted the current cases in which naltrexone were used for CRPS (Chopra, 2013).  
It is important to note that the treatment dosage of naltrexone used for CRPS is 
of an order of magnitude 50 times less than that used to combat opiate overdoes.  
A 46-year-old male suffering from severe CRPS for 4.5 years (Figure 8) was 
administered low doses of naltrexone after he had reported a pain scaling 10/10.  
After 2 months of treatment the pain fell to an average of a 5 or 6 out of 10 and 
the use of his cane (which he had used for 6 years) was no longer necessary.  
The patient experienced resolution of the ulceration on his leg as well as a 
marked increase in quality of life (Chopra, 2013).   
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Figure 8: Physical Presentation of CRPS in Lower Limb: (a) Severe CRPS 
and ulceration (b) in a patient prior to low dose naltrexone treatment (Chopra, 
2013) 
 
Another case of low dose naltrexone use involves a 12-year-old female 
suffering from color change, allodynia, and increased temperature of the affected 
limb.  Pain in the patient was reported at a minimum of 8/10 and a maximum of 
10/10.  After starting a treatment of 3mg naltrexone three times a day the dosage 
was increased to 4.5mg after 4 weeks.  Incredibly, the patient’s reported pain 
dropped to between 3 and 5 out of ten, complaints of alldynia diminished, and 
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temperature stabilized.  Additionally, the patient underwent surgery to correct 
destabilization in her ankle as a result of a pervious condition.  Following surgery, 
the use of low dose naltrexone was shown to have a greater effect on alleviating 
pain over oral opioids.  Astonishingly, after 18 months of naltrexone treatment, all 
symptoms of CRPS in the patient resolved with zero side effects reported.   
 It is still unclear what the direct cause of the hyperalgesia and allodynia 
experienced by CRPS patients, however the success of low dose naltrexone 
supports the growing belief that neuroinflammation is the culprit.  The 
suppression of overly active glia cells through naltrexone’s antagonistic 
properties and the subsequent decrease in the spread of neuroinflammation is 
promising for the treatment of CRPS.    
 
 
Thalidomide  
 
 Thalidomide was made popular in the 1950’s as an anti-anxiety and anti-
nausea medication prescribed mostly to pregnant women.  The use of 
thalidomide became widespread in Germany when the drug became available 
without the need for a prescription.  However, proper testing had not been 
conducted on the effect the drug has on a developing fetus, a misstep that 
resulted in thousands of children being born with birth defect after being exposed 
to thalidomide in the womb.  This shelved the use of thalidomide for a long time, 
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until its application in the treatment of multiple myeloma was discovered.  
Thalidomide, in conjunction with chemotherapy, has been shown to be effective 
in containing the proliferation of B-cells through direct apoptosis and G1 growth 
arrest (Frederica, 2008).  During clinical trials for the application of thalidomide to 
multiple myeloma, the resolution of RSD had unexpectedly been observed, 
prompting some to further investigate how thalidomide might be used as a 
treatment option for CRPS. 
 In 2003, Dr. Robert Schwartzman, while investigating ketamine’s use in 
CRPS, conducted a study investigating thalidomide’s treatment capability in 42 
CRPS patients (Schwartzman, 2003).  All 42 patients met the International 
Association for the Study of Pain diagnostic criteria mentioned earlier and had all 
failed pervious intervention.  The treatment dose of thalidomide was kept 
extremely low to start and none of the patients were pregnant, thus ensuring 
none of the negative properties of thalidomide’s use could be seen here.  Dr. 
Schwartzman used pain relief, healing of lesions, and increased function as the 
data points for the study.  17% of the 42 patients experienced a dramatic 
response in pain relief and an additional 14% reported some relief.  Side effects 
included rash, pain, edema, and solmnolence, all of which could be treated and 
prevented by using a lower dose of thalidomide (Schwartzman, 2003).   
 The results of Dr. Schwartzman’s study show that thalidomide has the 
potential to be a treatment option for CRPS.  The highly advanced CRPS 
patients used in this study had received all conventional treatments, thus making 
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the 17% that did experience drastic pain relief extremely promising.  The 
limitation with thalidomide, as we have seen with the majority of non-conventional 
CRPS treatments, is the severe lack of experimental evidence.  More controlled, 
double-blind studies need to be done as well as more observational clinical data 
into the use of these experimental treatments.  Thalidomide’s role in causing birth 
defects makes its use extremely dangerous and thus should only be 
administered in a tightly controlled setting.  Additionally, the negative side effects 
experienced by patients as a result of an elevated dosage should again render 
thalidomide’s use to a clinical setting.   
 
 
Vitamin C 
 
 Vitamin C may not instinctually seem to play a role in CRPS; however 
recent studies appear to indicate that ascorbic acid (vitamin C) can act as a 
preventative measure against CRPS.  Dr. Paul Zollinger and his team have been 
investigating ascorbic acid’s preventative properties in CRPS for almost 15 years 
and have reported promising results based on several clinical trials (Zollinger, 
1999).  Vitamin C’s potential role in CRPS treatment is fueled by the role oxygen 
radicals play in the pathogenesis of CRPS.  The belief that oxygen radicals are 
responsible for the sympathetic microcirculatory disturbances experienced in the 
initial development of CRPS, served as the inspiration for Dr. Zollinger’s use of 
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vitamin C. Furthermore, it has been shown that vitamin C acts on the epithelial 
cells of the microvasculature to prevent capillary permeability and edema 
(Tanaka, 2000).  The methodology of vitamin C’s actions on the microvasculature 
of epithelial cells comes from the reduction of lipid peroxidase, which has been 
shown to increase vascular permeability following burns.  Furthermore, vitamin C 
is an anti-oxidant that breaks down lipid peroxide, through the activation of 
vitamin E.   
 Microvascular permeability and leakage following a trauma does not 
directly result in CRPS, however the secondary inflammation that follows can.  
This is where vitamin C’s ability to prevent leakage and edema connects to 
CRPS.  Edema is followed by inflammation, and as noted previously, 
inflammation of peripheral nerves can lead to CRPS.  If vitamin C is able to 
reduce the microvascular damage associated with the limb traumas that typically 
give rise to CRPS, theoretically its use as could greatly reduce the instance of 
CRPS.  
 The first clinical trial investigating ascorbic acid’s preventative properties 
was a simple comparison measuring the rates of post-traumatic RSD in patients 
with wrist fractures.  The experimental group was treated with 500mg ascorbic 
acid from the time of the injury until a period of 50 days.  The other group 
received a placebo in parallel with the experimental group.  Patients in both 
groups were treated for a period of 50 days, and evaluated for one year, during 
which RSD was diagnosed upon the presence of four of the following six 
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symptoms: unexplained diffuse pain, redness of the skin, increased temperature 
of the skin, diffuse edema, limited motion, and the onset of any of these 
symptoms upon physical activity.  
 In total 146 patients were participated of which 57 received vitamin C 
treatments.  It can be seen from Figure 9 that wrist dominance, fracture type, and 
side of the fracture do not play a role in RSD development.  However, sex 
appears to be a significant variable in the patients that did develop RSD.  
Furthermore, it was noted that all of the female patients were postmenopausal; 
suggesting that estrogen level or even osteoporosis could be areas of future 
research.  It is not surprising though that more women developed RSD, as this is 
typical of the CRPS demographic.  Of the patients taking the vitamin C treatment, 
only 4 developed RSD, while 14 of the 51 patients taking the placebo developed 
RSD.  The most striking, and promising, statistic comes from the comparison of 
the patients who did develop RSD.  22% of the patients who developed RSD 
were on the vitamin C treatment, while a striking 78% were in the placebo group 
(Zollinger, 1999).   
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Figure 9: A Controlled Study of Vitamin C’s Preventative Potential in RSD: 
The results of Dr. Zollinger’s double-blind study show relatively standard 
outcomes with the exception of the remarkable difference between RSD patients 
receiving vitamin C treatment (Zollinger, 1999). 
 
 
 
 Dr. Zollinger followed up his 1999 study by conducting an additional 
experiment, again using wrist injury as a precursory trauma in CRPS 
development (Zollinger, 2007).  The results mirrored those of the previous study, 
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again showing a strong statistical advantage in the prevention of CRPS from the 
use of high dose vitamin C.  Dr. Zollinger’s data suggests that vitamin C can be 
used as a low-risk, preventative treatment for the development of CRPS, 
following minor trauma to the limbs.  Based on vitamin C’s known ability to 
prevent edema and microvascular capillary leakage, the reduction in 
inflammation and subsequent neuroinflammation following trauma holds strong 
potential to the prevention of CRPS.  Additionally, the use of high dose vitamin C 
doesn’t propose any adverse effects to patients following trauma to the limbs.  It 
is already recommended by the FDA that persons greater than age 19 consume 
at least 90mg of vitamin C a day, and the risk of overdose is extremely low.  A 
standard treatment plan for CRPS is still yet to be established, making disease 
resolution difficult.  If prevention is at all possible, a 50 day vitamin C course 
would seem prudent following limb trauma.   
 
 
High Dose Capsaicin  
 
 Capsaicin is the active ingredient found in chili peppers, which is 
responsible for their notorious burning sensation.  When put in contact with the 
skin, even very low doses of capsaicin are known to cause an intense and 
unpleasant burning (Robbins, 1998).  The burning sensation experienced by the 
initial application of capsaicin to the skin is the result of the excitation of neurons 
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which is then followed by a period of enhanced sensitivity (Mason, 2004).  
Following a period of hypersensitivity and neuron excitability is a refractory period 
marked by desensitization.  In patients with neuropathic pain, especially those 
experiencing hyperalgesia, a period of desensitization could result in the 
alleviation of pain.   
 Although capsaicin has been studied for the alleviation of pain before, only 
one study has investigated its specific use in CRPS.  Capsaicin creams were 
concentrated to one of four experimental doses: 0.05, 0.075, and 0.10 percent.  
Ten patients were selected for the study in which one of the three doses of 
capsaicin was applied to the area of the body experiencing hyperalgesia.  
Remarkably the pain associated with the capsaicin treatment lasted up to 7 days 
for some patients in the trial, although on a diminishing basis.  Over the course of 
a week following the initial capsaicin treatment, 9 of the 10 patients reported 
alleviation in pain and increased utilization of the affected area (Figure 10).  
Some patients reported an increased ability to bear weight on affected limbs, 
while another patient reported a drop in hyperalgesia great enough to permit 
wearing a shoe a foot severely affected with CRPS (Robbins, 1998).    
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Figure 10: Alleviation of Pain Upon Capsaicin Treatment: Each graph  
represents one of the patients in the clinical trial for capsaicin treatment.  The 
arrows above each of the graphs indicates the time at which capsaicin was 
administered.  The decline in pain experienced by each patient is evident 
(Robbins, 1998). 
 
 
The limitations of capsaicin treatments are obvious.  Application of 
capsaicin at doses even 2 orders of magnitude higher than commercially 
available results in dramatic pain, which in the case of Dr. Mason’s study 
mentioned above, treatment with opioids, became necessary for all participating 
patients.  However in neuropathic pain as severe as CRPS, radical treatments 
like this have a role.  Patients who have exhausted all other treatment options 
would be willing to undergo unconventional treatments such as topical capsaicin.  
As mentioned previously, CRPS manifests differently in every patient and 
treatment options today have varied in efficacy.  Some treatments work 
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especially well for some patients, while others have no effect.  When trying to 
combat a disease as frustrating and elusive as CRPS, all treatments options 
should be considered on an ongoing basis.  Physicians are charged with 
monitoring each individual treatment option and must not be afraid to change 
course if necessary.  Until we have a firmer grasp on CRPS, a wide array of 
treatment options is available and must be considered. 
 
 
 
DISCUSSION  
 
 This review has examined multiple treatment options, some that have 
been traditionally used for the treatment of CRPS and others that are 
experimental.  What has been made clear is that CRPS is a dynamic disease 
that still escapes our full understanding.  Although not a singular curable 
treatment exists, there is a wide range of treatment options that can be used to 
manage the symptoms of CRPS.   
A disturbing reality of CRPS treatment is the number and severity of side 
effects that accompany many of the treatment options.  The use of opioids is 
often unavoidable when treating pain of the magnitude experienced by CRPS 
patients.  However, the ever expanding issue of opioid dependence, tolerance, 
and abuse cannot be ignored.  Thus the niche for opioids in the treatment of 
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CRPS falls in the acute phase and only for short duration of utilization.  The 
efficacy of opioids cannot be denied, however over time as tolerance builds, they 
lose potency and leave patients at risk for dependence and overdose.  It is 
paramount that physicians are aware of the pitfalls associated with their use and 
administer them in a tightly controlled manner.  
 Most of the treatment options available for CRPS are hindered by negative 
side effects.  Gabapentin eludes these limitations and has been established as 
one of the fundamental treatment options for CRPS.  Experimental and 
observational data have shown that gabapentin possess pain alleviating 
properties, but it’s the drugs complimentary relationship with other treatments 
that makes it such an asset for treatment.  Gabapentin should be utilized at the 
forefront of CRPS treatment, and should absolutely be prescribed in any instance 
where opioids are administered.  The additive effect gabapentin has on opiates 
diminishes the need for incremental doses and mitigates some of the dangerous 
side effects of opiates.    
 Antidepressants role in treating neuropathic pain is another highlight found 
from this review.  Antidepressants have a strong role in combating the 
depression experienced by CRPS compliments their ability to also alleviate 
neuropathic pain.  Antidepressants, TCAs in particular, exhibit minimal side 
effects and have been shown to intensify the analgesic effects of opioids.  This 
makes their use both low risk and highly effective and should be a first choice 
when treating CRPS. 
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  The evidence supporting sympathetic blocks for CRPS treatment is fair to 
poor.  Promising data was invalidated by conflicting reports of lidocaine’s efficacy 
in relieving pain symptoms.  Furthermore, some of the more general overview 
studies of CRPS suggested the discontinued use of sympathetic block all 
together (Forouzanfar, 2002).  From the data observed in this study, the efficacy 
of sympathetic block remains a bit of a mystery and requires further experimental 
data.  Clearly some benefit has been observed in the past, as sympathetic block 
has been used in the treatment of CRPS for some time; however the extent of its 
use and optimal method of implementation requires further study.    
 The results of some of the new experimental treatments for CRPS are 
encouraging, especially the use of low dose naltrexone. Thalidomide, naltrexone, 
and Ketamine have all been shown to be extremely effective in alleviating pain in 
CRPS patients, however remain underutilized in current treatment.  Ketamine 
has proven effective but requires close monitoring during administration.  Future 
studies are needed on the optimal Ketamine dosage and methodology of the 
drug.  Thalidomide and naltrexone have only just recently entered the 
conversation, however initial clinical trials show good results.  Additional studies 
and observational data on these treatments have the potential to unlock a more 
effective treatment plan than currently available.   
 Finally, some of the more fringe treatments include vitamin C and high 
dose capsaicin.  Vitamin C may be the most innocuous treatment for CRPS, 
even though its use is limited to a preventative role.  However, with rates of 
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CRPS developing following fracture reaching as high as 37%, the preventative 
use of vitamin C is reward with little risk (Atkins, 1990).  High dose capsaicin is a 
different story all together.  This treatment is extremely painful in itself and should 
really only be considered for the most severe and desperate cases.  Although 
very limited in the literature, the results reported for capsaicin’s use are 
encouraging.   
 Through an evaluation of various treatment options for CRPS, it is clear 
that one singular treatment isn’t sufficient.  Each patient falls in a unique position 
on the spectrum of CRPS, and a specific treatment course is necessary for each 
individual patient.  Physicians and patients are charged with the responsibility of 
constantly challenging and changing treatment options as they prove ineffective.  
It is important to note that other non-pharmacological interventions exist for 
CRPS.  As mentioned earlier, physical therapy early in CRPS development has 
proven to be effective and is a staple of treatment today.  Additionally, spinal cord 
stimulation in the latter stages of CRPS is widely used as an effective treatment.  
Furthermore, the volume of treatment options is enormous, which is a strong 
indicator of just how lost we are when it comes to CRPS (Birklein, 2005).  The 
ambiguity surrounding the disorder has created more of a shotgun approach to 
treatment instead of an efficient and targeted method.  Until we are able to lift the 
veil on CRPS, treatment has to be ever changing and evolving with each 
individual patient.    
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